Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.naturalcapsules.com | |
Market Cap | 285.61 Cr. | |
Enterprise Value(EV) | 367.42 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 7.75 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 39.40 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 136.32 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 2.24 | Calculated using Price: 305.50 |
Dividend Yield | 0.33 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.93 Cr. | 9,349,050 Shares |
FaceValue | 10 | |
About Natural Capsules Ltd. | ||
Natural Capsules is a public limited company established in the year 1993.The company is a well-equipped modern manufacturing plant to manufacture hard gelatin capsule shells, Hard cellulose capsule shells and pharmaceutical dosage forms in capsule dosage form. |
1 Day |
|
+0.08% |
1 Week |
|
-4.68% |
1 Month |
|
-7.52% |
3 Month |
|
-15.09% |
6 Month |
|
-21.01% |
1 Year |
|
-22.00% |
2 Year |
|
-30.14% |
5 Year |
|
+489.54% |
10 Year |
|
+1028.97% |
6 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 2.05 | 3.5 | 1.54 | 11.74 | 19.18 | 17.89 | |
Return on Capital Employed (%) | 3.71 | 4.51 | 3.71 | 14.52 | 20.75 | 16.18 | |
Return on Assets (%) | 1.56 | 2.66 | 1.16 | 8.05 | 10.65 | 8.14 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 54 | 55 | 56 | 62 | 83 | 123 | 126 | |
Non Curr. Liab. | 2 | 1 | 1 | 2 | 37 | 74 | 68 | |
Curr. Liab. | 15 | 16 | 18 | 33 | 45 | 67 | 73 | |
Minority Int. | 25 | 75 | ||||||
Equity & Liab. | 71 | 73 | 75 | 97 | 164 | 289 | 342 | |
Non Curr. Assets | 29 | 35 | 37 | 47 | 89 | 187 | 218 | |
Curr. Assets | 42 | 38 | 38 | 50 | 76 | 102 | 124 | |
Misc. Exp. not W/O | ||||||||
Total Assets | 71 | 73 | 75 | 97 | 164 | 289 | 342 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 55 | 60 | 62 | 80 | 135 | 172 | 153 | |
Other Income | 1 | 1 | 1 | 1 | 2 | 2 | 1 | |
Total Income | 56 | 61 | 63 | 80 | 137 | 174 | 154 | |
Total Expenditure | -49 | -55 | -56 | -68 | -111 | -138 | -130 | |
PBIDT | 6 | 6 | 6 | 12 | 27 | 36 | 24 | |
Interest | 0 | -1 | -1 | -1 | -2 | -4 | -5 | |
Depreciation | -4 | -3 | -4 | -4 | -5 | -7 | -8 | |
Taxation | -1 | 0 | -1 | -2 | -5 | -7 | -3 | |
Exceptional Items | 0 | 2 | ||||||
PAT | 1 | 2 | 1 | 7 | 14 | 18 | 7 | |
Minority Interest | ||||||||
Share Associate | ||||||||
Other Related Items | 0 | 0 | 0 | |||||
Consolidated Net Profit | 1 | 2 | 1 | 7 | 14 | 18 | 7 | |
Adjusted EPS | 1 | 3 | 1 | 9 | 20 | 20 | 8 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 5 | 2 | 7 | 6 | -1 | 17 | |
Cash Fr. Inv. | -1 | -7 | -6 | -9 | -46 | -105 | |
Cash Fr. Finan. | -4 | 4 | -1 | 3 | 48 | 87 | |
Net Change | 0 | -1 | 0 | 0 | 1 | 0 | |
Cash & Cash Eqvt | 1 | 0 | 0 | 0 | 1 | 1 |
Wed, 27 Mar 2024
Closure of Trading Window Pursuant to SEBI (PIT) Regulations 2015 and companys code of conduct for prevention of Insider Trading and code of corporate disclosure practices we wish to inform that the Trading window for dealing in the equity shares of the Company shall remain closed for all Designated Persons and their immediate relative with effect from 01.04.2024 till the conclusion of 48 hours after the declaration of financial results of the company for the period ended 31.03.2024. The date of Board Meeting of the Company for declaration of financial results shall be intimated in due course. |
Mon, 18 Mar 2024
Announcement Under Regulation 30 (LODR)-Commencement Of Commercial Production In High Speed HPMC Line Pursuant to the provisions of Regulation 30 of SEBI (LODR) we wish to inform you that the Company has initiated production in the first high speed HPMC line on 18.03.2024. Upon reaching full operational capacity the company will proceed with commercialization in second and third high speed HPMC lines. |
Fri, 15 Mar 2024
Announcement Under Regulation 30 (LODR)-Commencement Of Production Of Small Volume Batches Of Natural Biogenex Private Limited Subsidiary Of The Company Pursuant to the provisions of Regulation 30 of SEBI (LODR) We wish to inform you that M/S Natural Biogenex Private Limited Subsidiary of the Company has commenced production of small volume batches on 15th March 2024. |
Thu, 28 Mar 2024 |
High Delivery Percentage |
Opening at High |
Making Lower Lows for 3 days |
Close Within 52 Week Low Zone |
Close Below Last Month Low |